Phase 1 trial sponsored by Kura Oncology, Inc. under Protocol Number KO-MEN-008 entitled Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia. Attached for your consideration is a high-level overview of the trial.